Big readouts ahead for small biotechs
Nash data are due for Terns and Inventiva, as Marinus aims to expand its rare disease offering.
Black Diamond’s lung cancer pivot delivers
The company’s stock surges 236% on first data with its new EGFR project, so where’s the catch?
Easl 2023 – GLP-1 combos take on a milder form of Nash
Similarly acting agents from Merck & Co and Altimmune aim to improve NAFLD, with mixed results.
Lilly signs up Verve to take on Novartis and Amgen
Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.
Hope springs for April inhibition
Novartis’s Chinook takeout gives a boost to others pursuing this long-researched target, including Vera and Alpine.
Aerow hits the mark for 4D Molecular
An early success with its cystic fibrosis gene therapy brings the company up.